ePT--the Electronic Newsletter of Pharmaceutical Technology, Sep 13, 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

ePT--the Electronic Newsletter of Pharmaceutical Technology, Sep 13, 2012
News
Pfizer Settles Patent Litigation with Mylan
By Jennifer Markarian
Pfizer and Mylan have agreed on terms by which Mylan may launch its generic version of Pfizer's Detrol LA (tolterodine tartrate) extended-release capsules, pending final approval by FDA.
Eli Lilly Receives FDA Warning Letter
By Stephanie Sutton
Eli Lilly has received an FDA Warning Letter because of a "misleading" image of a multicolored brain that appeared on the company's website for the diagnostic PET tracer, Amyvid.
CDER to Expand Office of Generic Drugs
By Susan Haigney
As a result of the passage of the Generic Drug User Fee Amendments Act, Janet Woodcock, director of the Center for Drug Evaluation and Research, announced her plan to reorganize the Office of Generic Drugs (OGD) into a super office that would include subordinate offices. The new super office would report directly to Director Woodcock, with Greg Geba continuing his role as OGD director.
Despite Setbacks, PhRMA Awards Encourage Research into and Fight against Alzheimer's
By Angie Drakulich
Delaying the onset of Alzheimer's disease by just five years could reduce the cost for care of Alzheimer's patients by $447 billion a year by 2050, according to a new PhRMA report.
Just Announced: PhRMA's Research and Hope Award Recipients
By Angie Drakulich
John Castellani, President of PhRMA, talks to PharmTech about its 2012 Research and Hope Award recipients.
Week of September 10, 2012: Cambridge Major Laboratories Expands API Manufacturing Facility; Spectrum Completes Acquisition of Allos Therapeutics; and More
Cambridge Major Laboratories Expands API Manufacturing Facility; Spectrum Completes Acquisition of Allos Therapeutics; and More.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
Click here